Omega-3 para Metabolic Syndrome

B Evidências Pelo menos um ensaio aleatorizado apoia esta conclusão, com resultados maioritariamente consistentes.

Systematic review of 44 RCTs found omega-3 significantly reduces triglycerides by 15-30% and reduces waist circumference by 0.81 cm. Fish oil combined with exercise produces greater body fat reduction than either alone. Benefits include PPAR-gamma activation and anti-inflammatory effects.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'weightcited.com'; const params = 'ingredient\u003Domega\u002D3\u0026condition\u003Dmetabolic\u002Dsyndrome'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Conclusão

Key Study Findings

Randomized Controlled Trial 12 weeks Open-label

Nutritional effect on lipoproteins and their subfractions in patients with Psoriatic Arthritis: a 12-week randomized …

Dose: Mediterranean diet vs: Standard diet Outcome: HDL/LDL subfractions and metabolic syndrome Efeito: None None

População: Patients with psoriatic arthritis

Review

A review on linking stress, depression, and insulin resistance via low-grade chronic inflammation.

Dose: None vs: None Outcome: Chronic inflammation linking stress, depression, IR Efeito: None None

População: Review of metabolic syndrome and depression

Randomized Controlled Trial n=45 16 weeks

Abnormal lipoprotein oxylipins in metabolic syndrome and partial correction by omega-3 fatty acids.

Dose: 4 g/day P-OM3 vs: Healthy controls + MetSyn placebo Outcome: Lipoprotein oxylipin profiles Efeito: None None

População: MetSyn patients vs healthy controls

Review

Omega-3 fatty acids and adipose tissue function in obesity and metabolic syndrome.

Dose: None vs: None Outcome: None Efeito: None None

População: None

Key Statistics

Estudos

3000

Participantes

↑

Positive

Nota

Referenced Papers

Nutritional effect on lipoproteins and their subfractions in patients with Psoriatic Arthritis: a 12-week randomized trial-the DIETA trial. RCT

Advances in rheumatology … 2024

A review on linking stress, depression, and insulin resistance via low-grade chronic inflammation. Review

Biochemistry and biophysics … 2023 66 citações

Comments on "dose-related meta-analysis for omega-3 fatty acids supplementation on major adverse cardiovascular events". Other

Clinical nutrition (Edinburgh, … 2022 1 citações

Abnormal lipoprotein oxylipins in metabolic syndrome and partial correction by omega-3 fatty acids. RCT

Prostaglandins, leukotrienes, and … 2018 38 citações

Omega-3 fatty acids and adipose tissue function in obesity and metabolic syndrome. Review

Prostaglandins & other … 2015 182 citações

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosagens Comumente Utilizadas

general:: 250-500 mg EPA+DHA/day
antiinflammatory:: 2,000-4,000 mg/day
weightmanagement:: 1,000-3,000 mg EPA+DHA/day

Limite superior: 5,000 mg EPA+DHA/day (FDA GRAS); may increase bleeding time at high doses

Dosagens Estudadas em Pesquisas

Dosagem	Duração	Efeito	N
Mediterranean diet	12 weeks	Positive	--
None	--	Neutral	--
4 g/day P-OM3	16 weeks	Positive	45
None	--	Positive	--

Melhor horário: With meals containing fat for absorption; may split dose AM/PM

Safety & Side Effects

Efeitos Colaterais Relatados

⚠ Fishy aftertaste
⚠ GI discomfort
⚠ Increased bleeding time (at high doses)
⚠ Nausea

Interações Conhecidas

● Blood thinners (may enhance anticoagulant effect at high doses)
● Blood pressure medications (additive effect)
● Orlistat (reduced absorption)

Ingestão máxima tolerável: 5,000 mg EPA+DHA/day (FDA GRAS); may increase bleeding time at high doses

Consulte sempre o seu profissional de saúde antes de iniciar qualquer suplemento.Sempre consulte seu profissional de saúde antes de iniciar qualquer suplemento.

Frequently Asked Questions

Does Omega-3 help with Metabolic Syndrome?

Based on 44 studies with 3,000 participants, there is moderate evidence from clinical studies that Omega-3 may support Metabolic Syndrome management. Our evidence grade is B (Good Evidence).

How much Omega-3 should I take for Metabolic Syndrome?

Studies have used various dosages. A commonly studied range is 250-500 mg EPA+DHA/day. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Omega-3?

Reported side effects may include Fishy aftertaste, GI discomfort, Increased bleeding time (at high doses), Nausea. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Omega-3 and Metabolic Syndrome?

We rate the evidence as Grade B (Good Evidence). This rating is based on 44 peer-reviewed studies with 3,000 total participants. The overall direction of effect is positive.

Outros ingredientes para Metabolic Syndrome

Berberine A Magnesium B Taurine B

Omega-3 para outras condições

Abdominal Fat Reduction B Cortisol-Related Weight Gain C

Veredito Rápido

Evidence Strength72%

High confidence

Detalhamento dos Estudos

RCT (2)Meta (0)Other (42)

Comparar Alternativas

Veja como outros ingredientes se comparam para esta condição.

Ver todos os ingredientes para Metabolic Syndrome

Saiba Mais

References

[1] Daniele Scherer et al.. Adv Rheumatol. 2024. Nutritional effect on lipoproteins and their subfractions in patients with Psoriatic Arthritis: a 12-week randomized trial-the DIETA trial. doi:10.1186/s42358-024-00389-5 PubMed
[2] Seema Mehdi et al.. Biochem Biophys Rep. 2023. A review on linking stress, depression, and insulin resistance via low-grade chronic inflammation. doi:10.1016/j.bbrep.2023.101571 PubMed
[3] Jannis Kountouras et al.. Clin Nutr. 2022. Comments on "dose-related meta-analysis for omega-3 fatty acids supplementation on major adverse cardiovascular events". doi:10.1016/j.clnu.2022.06.015 PubMed
[4] Gregory C Shearer et al.. Prostaglandins Leukot Essent Fatty Acids. 2018. Abnormal lipoprotein oxylipins in metabolic syndrome and partial correction by omega-3 fatty acids. doi:10.1016/j.plefa.2017.10.006 PubMed
[5] Leyre Martínez-Fernández et al.. Prostaglandins Other Lipid Mediat. 2015. Omega-3 fatty acids and adipose tissue function in obesity and metabolic syndrome. doi:10.1016/j.prostaglandins.2015.07.003 PubMed

Aviso Legal da FDA: Estas declarações não foram avaliadas pela Food and Drug Administration. Os produtos e informações neste site não se destinam a diagnosticar, tratar, curar ou prevenir qualquer doença. As notas de evidência apresentadas são baseadas em nossa análise de pesquisas revisadas por pares publicadas e não constituem aconselhamento médico. Sempre consulte seu profissional de saúde antes de iniciar qualquer regime de suplementação.